Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
The Maire - EuroChem Case: Three Lessons for Global Business 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
NEW YORK, May 17, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:
- UBS Global Healthcare Conference on May 23, 2017 at 2:30 p.m. Eastern Time
- Jefferies Healthcare Conference on June 8, 2017 at 2:00 p.m. Eastern Time
- Goldman Sachs 38th Annual Healthcare Conference on June 13, 2017 at 11:20 a.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
